ATE435852T1 - Gpe-analoga und peptidomimetika - Google Patents
Gpe-analoga und peptidomimetikaInfo
- Publication number
- ATE435852T1 ATE435852T1 AT02731918T AT02731918T ATE435852T1 AT E435852 T1 ATE435852 T1 AT E435852T1 AT 02731918 T AT02731918 T AT 02731918T AT 02731918 T AT02731918 T AT 02731918T AT E435852 T1 ATE435852 T1 AT E435852T1
- Authority
- AT
- Austria
- Prior art keywords
- peptidomimetics
- gpe
- analogue
- analogs
- relates
- Prior art date
Links
- 239000000816 peptidomimetic Substances 0.000 title abstract 3
- JJGBXTYGTKWGAT-YUMQZZPRSA-N Gly-Pro-Glu Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O JJGBXTYGTKWGAT-YUMQZZPRSA-N 0.000 abstract 3
- 230000002424 anti-apoptotic effect Effects 0.000 abstract 1
- 230000000421 anti-necrotic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Crystallography & Structural Chemistry (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Combined Controls Of Internal Combustion Engines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29385301P | 2001-05-24 | 2001-05-24 | |
| PCT/US2002/016361 WO2002094856A2 (en) | 2001-05-24 | 2002-05-24 | Gpe analogs and peptidomimetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE435852T1 true ATE435852T1 (de) | 2009-07-15 |
Family
ID=23130863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02731918T ATE435852T1 (de) | 2001-05-24 | 2002-05-24 | Gpe-analoga und peptidomimetika |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7041314B2 (de) |
| EP (1) | EP1401808B1 (de) |
| JP (1) | JP2004536069A (de) |
| AT (1) | ATE435852T1 (de) |
| AU (1) | AU2002303856A1 (de) |
| DE (1) | DE60232880D1 (de) |
| ES (1) | ES2325983T3 (de) |
| WO (1) | WO2002094856A2 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1401808B1 (de) | 2001-05-24 | 2009-07-08 | Neuren Pharmaceuticals Limited | Gpe-analoga und peptidomimetika |
| US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
| WO2006127702A2 (en) * | 2005-05-23 | 2006-11-30 | Neuren Pharmaceuticals Limited | Analogs of glycyl-prolyl-glutamate |
| US20070004641A1 (en) * | 2001-05-24 | 2007-01-04 | Neuren Pharmaceuticals Limited | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate |
| US7863304B2 (en) * | 2001-05-24 | 2011-01-04 | Neuren Pharmaceuticals Limited | Analogs of glycyl-prolyl-glutamate |
| US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
| US7485630B2 (en) * | 2003-03-20 | 2009-02-03 | Neuren Pharmaceuticals Limited | Neuroprotective macrocyclic compounds and methods for their use |
| CN101198354B (zh) | 2005-06-21 | 2012-01-11 | 兴和株式会社 | 青光眼的预防或治疗剂 |
| JP5220724B2 (ja) * | 2006-03-14 | 2013-06-26 | ニューレン ファーマシューティカルズ リミテッド | グリシル−２−メチルプロリルグルタミン酸塩の経口製剤 |
| CA2689549A1 (en) * | 2007-06-08 | 2008-12-18 | Massachusetts Institute Of Technology | Igf for the treatment of rett syndrome and synaptic disorders |
| JP2009016396A (ja) * | 2007-06-29 | 2009-01-22 | Optical Comb Inc | 波長走査型ファイバレーザ光源 |
| EP2338492A1 (de) * | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Verfahren und Zusammensetzung zur Behandlung von Alzheimer |
| US9708366B2 (en) | 2011-01-27 | 2017-07-18 | Neuren Pharmaceuticals Ltd. | Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate |
| AU2013352294A1 (en) * | 2012-11-28 | 2015-07-09 | Neuren Pharmaceuticals Limited | Treatment of Autism Spectrum Disorders using glycyl-l-2-methylprolyl-l-glutamic acid |
| DK3049428T3 (en) | 2013-09-23 | 2019-03-04 | Dr August Wolff Gmbh & Co Kg Arzneimittel | ANTI-INFLAMMATORY TRIPEPTIDES |
| KR20220059479A (ko) | 2019-08-05 | 2022-05-10 | 뉴렌 파마슈티컬즈 리미티드 | 트로피네타이드의 조성물 |
| IL310045A (en) | 2021-07-12 | 2024-03-01 | Acadia Pharm Inc | Crystalline forms of tropintide |
| CN120000765A (zh) * | 2025-03-28 | 2025-05-16 | 首都医科大学宣武医院 | 一种gpe类似物在制备预防和/或治疗阿尔茨海默病的药物中的用途 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444879A (en) | 1981-01-29 | 1984-04-24 | Science Research Center, Inc. | Immunoassay with article having support film and immunological counterpart of analyte |
| US4699875A (en) | 1982-11-24 | 1987-10-13 | Baylor College Of Medicine | Diagnosis of amyotrophic lateral sclerosis by neurotrophic factors |
| US5618697A (en) | 1982-12-10 | 1997-04-08 | Novo Nordisk A/S | Process for preparing a desired protein |
| DK55685A (da) | 1985-02-07 | 1986-08-08 | Nordisk Gentofte | Enzym eller enzymkompleks med proteolytisk aktivitet |
| US4511390A (en) | 1983-06-10 | 1985-04-16 | E. I. Du Pont De Nemours And Company | Aralkylcarbamoyl peptide alcohols |
| US5149657A (en) | 1984-09-13 | 1992-09-22 | Enzon Labs Inc. | Escherichia coli expression vector encoding bioadhesive precursor protein analogs comprising three to twenty repeats of the decapeptide (Ala-Lys-Pro-Ser-Tyr-Pro-Pro-Thr-Tyr-Lys) |
| DE3502041A1 (de) | 1985-01-23 | 1986-07-24 | Grünenthal GmbH, 5190 Stolberg | Verwendung von dipeptidderivaten zur behandlung posttraumatischer nervenschaeden |
| US4783524A (en) | 1985-09-17 | 1988-11-08 | Monsanto Company | Growth factors |
| SE8505920D0 (sv) | 1985-12-13 | 1985-12-13 | Kabigen Ab | New protein and its use |
| US5496712A (en) | 1990-11-06 | 1996-03-05 | Protein Polymer | High molecular weight collagen-like protein polymers |
| AU612340B2 (en) | 1986-11-04 | 1991-07-11 | Protein Polymers Technologies, Inc. | Construction of synthetic dna and its use in large polypeptide synthesis |
| US5243038A (en) | 1986-11-04 | 1993-09-07 | Protein Polymer Technologies, Inc. | Construction of synthetic DNA and its use in large polypeptide synthesis |
| US5089406A (en) | 1987-01-07 | 1992-02-18 | Allied-Signal Inc. | Method of producing a gene cassette coding for polypeptides with repeating amino acid sequences |
| EP0289314B1 (de) | 1987-04-28 | 1994-10-12 | Roche Diagnostics GmbH | Verwendung von IGF-II zur Behandlung von Knochenkrankheiten |
| US4923696A (en) | 1987-05-04 | 1990-05-08 | Baylor College Of Medicine | Method to prepare a neurotrophic composition |
| IL86423A0 (en) | 1987-05-19 | 1988-11-15 | Baylor College Medicine | Pharmaceutical compositions for the treatment of alzheimer's disease |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| SE8703625D0 (sv) | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | New medical use |
| ATE116335T1 (de) | 1987-12-24 | 1995-01-15 | Gropep Pty Ltd | Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2). |
| EP0327503B1 (de) | 1988-02-05 | 1993-03-10 | Ciba-Geigy Ag | Verwendung von IGF I zur Herstellung eines Präparates für die Behandlung von Nierenkrankheiten |
| US5057494A (en) | 1988-08-03 | 1991-10-15 | Ethicon, Inc. | Method for preventing tissue damage after an ischemic episode |
| SE8803847A0 (sv) * | 1988-10-27 | 1990-04-28 | Kabigen Ab | Neuromodulerande peptid |
| DE68928532T2 (de) | 1988-11-09 | 1998-05-28 | Protein Polymer Tech Inc | Funktionelles, durch ein rekombinantes verfahren hergestelltes synthetisches proteinpolymer |
| US5093317A (en) | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| US5652214A (en) | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
| US5114840A (en) | 1989-07-07 | 1992-05-19 | Karl Tryggvason | Method for determining the nucleotide sequence of a novel α5(IV) chain of human type IV collagen |
| EP0816505B1 (de) | 1990-11-28 | 2003-09-24 | E.I. Du Pont De Nemours And Company | Strukturproteine durch künstliche Gene |
| US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
| EP0597033B1 (de) | 1991-08-01 | 1997-04-09 | Genentech, Inc. | IGF-I zur Verbesserung der neuronale Lage |
| US5861373A (en) | 1991-08-01 | 1999-01-19 | Genentech, Inc | IGF-1 to improve the neural condition |
| WO1993008828A1 (en) | 1991-11-08 | 1993-05-13 | Syntex-Synergen Neuroscience Joint Venture | Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration |
| US6310040B1 (en) | 1991-11-08 | 2001-10-30 | Cephalon, Inc. | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
| EP0615452A4 (de) | 1991-11-25 | 1995-07-12 | Inst Molecular Biology Inc | Medikament zur unterstützung des wachstums von nerven in säugetieren. |
| US5439930A (en) * | 1992-04-14 | 1995-08-08 | Russian-American Institute For New Drug Development | Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects |
| US5420112A (en) | 1992-06-12 | 1995-05-30 | Lewis; Michael E. | Prevention and treatment of peripheral neuropathy |
| HU217543B (hu) | 1992-06-12 | 2000-02-28 | Albert Einstein College Of Medicine Of Yeshiva University | Eljárás perifériás neuropátia kezelésére és megelőzésére alkalmas gyógyászati készítmények előállítására, valamint inzulinszerű növekedési faktor I-et és kemoterápiás szert tartalmazó gyógyászati készítmények |
| US5273961A (en) | 1992-09-22 | 1993-12-28 | Genentech, Inc. | Method of prophylaxis of acute renal failure |
| PT696205E (pt) | 1993-04-13 | 2002-07-31 | Us Gov Health & Human Serv | Utilizacao de linhas celulares fetais nauro-derivadas para terapia de transplantacao |
| SE9301667D0 (sv) | 1993-05-14 | 1993-05-14 | Kabi Pharmacia Ab | New use |
| FR2707170A1 (fr) | 1993-06-04 | 1995-01-13 | Pasteur Institut | Expression des récepteurs CD4 et CD26 dans des cellules recombinantes, inhibiteurs du récepteur CD26. |
| US5639729A (en) | 1993-08-26 | 1997-06-17 | Immunobiology Research Institute, Inc. | Tripeptides useful in immune and CNS therapy |
| AU693489B2 (en) | 1993-11-15 | 1998-07-02 | Celtrix Pharmaceuticals, Inc. | Method of treating neurological disorders |
| US5451660A (en) | 1993-12-13 | 1995-09-19 | Genentech, Inc. | Method for purifying polypeptides |
| WO1995017204A1 (en) | 1993-12-23 | 1995-06-29 | Auckland Uniservices Limited | Composition and methods to improve neural outcome |
| US6812208B2 (en) * | 1993-12-23 | 2004-11-02 | Neuronz Ltd. | Methods to improve neural outcome |
| JPH09511486A (ja) | 1994-01-13 | 1997-11-18 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 合成レセプター、ライブラリー及びこれらの使用 |
| US5710252A (en) | 1995-02-03 | 1998-01-20 | Eastman Kodak Company | Method for recombinant yeast expression and isolation of water-soluble collagen-type polypeptides |
| US5670616A (en) | 1995-02-03 | 1997-09-23 | Eastman Kodak Company | Collagen-like polypeptides and biopolymers and nucleic acids encoding same |
| US5965531A (en) | 1995-08-31 | 1999-10-12 | National Institutes Of Health | Method of reducing perivascular lesions using insulin-like growth factor I |
| AU7719596A (en) | 1995-11-07 | 1997-05-29 | Baylor College Of Medicine | Adenovirus-mediated production of bioactive proteins by mammalian cells and animals |
| US5686423A (en) | 1996-02-16 | 1997-11-11 | Department Of Health, The Executive Yuan, Republic Of China | Di-and tri-peptide mimetic compounds for Parkinson's disease |
| CA2224859A1 (en) | 1996-04-17 | 1997-10-23 | Amitabh Gaur | Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor |
| TR199802584T2 (xx) | 1996-06-11 | 1999-03-22 | Boehringer Mannheim Gmbh | Denat�re proteinin aktive edilmesi i�in y�ntem. |
| ATE301459T1 (de) | 1996-09-18 | 2005-08-15 | Applied Genetics Inc Dermatics | Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen |
| US6365573B1 (en) | 1996-10-04 | 2002-04-02 | Neuronz Ltd. | Regulation of neural enzymes |
| WO1998052620A2 (en) | 1997-05-16 | 1998-11-26 | Novartis Ag | Collagen-like polymers with cell binding activity |
| US6054579A (en) * | 1997-06-26 | 2000-04-25 | Leukosite, Inc. | Synthesis of substituted lactams |
| US6187906B1 (en) | 1997-08-11 | 2001-02-13 | Aukland Uniservices Limited | Methods to improve neural outcome |
| US6013253A (en) | 1997-08-15 | 2000-01-11 | Amgen, Inc. | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
| AU738192B2 (en) | 1997-09-19 | 2001-09-13 | Neuren Pharmaceuticals Limited | Neuronal rescue agent |
| CA2319828A1 (en) | 1998-01-29 | 1999-08-05 | Miller, Samuel | High density arrays for proteome analysis and methods and compositions therefor |
| EP1087782A4 (de) | 1998-06-15 | 2001-09-12 | Neuronz Ltd | Regulation der tyrosinhydroxylase |
| EP1109572A4 (de) | 1998-09-03 | 2004-11-24 | Neuronz Ltd | Neuroprotektion |
| US6444657B1 (en) | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
| EP1043027A1 (de) | 1999-04-08 | 2000-10-11 | Applied Research Systems ARS Holding N.V. | Behandlung von multiplersklerose mit einer kombination von interferon und Wachstumshormone |
| AU2001289160A1 (en) | 2000-08-24 | 2002-03-04 | Neuronz Ltd. | Gpe analogs |
| US20030027755A1 (en) | 2000-12-08 | 2003-02-06 | Jian Guan | Compositions and methods for the rescue of white matter |
| US20020177239A1 (en) | 2001-03-16 | 2002-11-28 | Thomas Gregory Brian | Anti-GPE antibodies, their uses, and analytical methods for GPE |
| US6682753B2 (en) * | 2001-03-23 | 2004-01-27 | Neuronz Limited | Methods for promoting weight gain using GPE-related compounds |
| US7018642B2 (en) * | 2001-04-27 | 2006-03-28 | The Procter & Gamble Company | Compounds, compositions, and methods for controlling biofilms |
| EP1401808B1 (de) | 2001-05-24 | 2009-07-08 | Neuren Pharmaceuticals Limited | Gpe-analoga und peptidomimetika |
| AU2002335657A1 (en) | 2001-08-24 | 2003-03-10 | Neuronz Biosciences, Inc. | Neural regeneration peptide and methods for their use in treatment of brain damage |
-
2002
- 2002-05-24 EP EP02731918A patent/EP1401808B1/de not_active Expired - Lifetime
- 2002-05-24 US US10/155,864 patent/US7041314B2/en not_active Expired - Lifetime
- 2002-05-24 AT AT02731918T patent/ATE435852T1/de not_active IP Right Cessation
- 2002-05-24 AU AU2002303856A patent/AU2002303856A1/en not_active Abandoned
- 2002-05-24 ES ES02731918T patent/ES2325983T3/es not_active Expired - Lifetime
- 2002-05-24 WO PCT/US2002/016361 patent/WO2002094856A2/en not_active Ceased
- 2002-05-24 JP JP2002592330A patent/JP2004536069A/ja active Pending
- 2002-05-24 DE DE60232880T patent/DE60232880D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US7041314B2 (en) | 2006-05-09 |
| ES2325983T3 (es) | 2009-09-28 |
| WO2002094856A2 (en) | 2002-11-28 |
| AU2002303856A1 (en) | 2002-12-03 |
| EP1401808A2 (de) | 2004-03-31 |
| DE60232880D1 (de) | 2009-08-20 |
| EP1401808B1 (de) | 2009-07-08 |
| JP2004536069A (ja) | 2004-12-02 |
| US20030055004A1 (en) | 2003-03-20 |
| WO2002094856A3 (en) | 2003-05-15 |
| EP1401808A4 (de) | 2004-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60232880D1 (de) | Gpe-analoga und peptidomimetika | |
| ATE486587T1 (de) | Formulierungen zur oralen verabreichung von wirkstoffen | |
| NO20051102L (no) | Sulfonylamino-eddiksyre-derivater | |
| BG66084B1 (bg) | Циклопентаноиндоли, състави,съдържащи такива съединения и използването им | |
| ATE435210T1 (de) | Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten | |
| NO20034230L (no) | 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister | |
| SE0301009D0 (sv) | Novel compounds | |
| ATE286500T1 (de) | 1,2,3,4-tetrahydroisochinolin-derivate | |
| IL232501A (en) | Peptide or polypeptide-resistant protein analogs and their uses | |
| BRPI0418251C1 (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo | |
| ATE433447T1 (de) | Pyrimiidinverbindungen | |
| MEP90508A (en) | New pharmaceutical composition | |
| DE60214179D1 (de) | IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN | |
| MY139690A (en) | Sulfonamide derivatives for the treatment of diseases. | |
| MY143390A (en) | Sulfonamide derivatives for the treatment of diseases. | |
| EA200970132A1 (ru) | Аналоги морфолинила и пирролидинила | |
| ATE273690T1 (de) | Zusammensetzung zur hautdesinfizierung | |
| MXPA03010158A (es) | Sulfonamidas. | |
| EP1423137A4 (de) | Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte | |
| GEAP202415866A (en) | 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents | |
| ATE432278T1 (de) | Verbindungen zur behandlung von krankheiten | |
| NO20073762L (no) | Visko-supplementsammensetning og fremgangsmater | |
| ATE383345T1 (de) | Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten. | |
| MEP34308A (en) | Oral formulations of cladribine | |
| DE602004019528D1 (de) | Usammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |